179 related articles for article (PubMed ID: 32340631)
1. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
Feng X; Kim DD; Cohen JT; Neumann PJ; Ollendorf DA
Int J Technol Assess Health Care; 2020 Apr; 36(2):96-103. PubMed ID: 32340631
[TBL] [Abstract][Full Text] [Related]
2. Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review.
Rios-Diaz AJ; Lam J; Ramos MS; Moscoso AV; Vaughn P; Zogg CK; Caterson EJ
PLoS One; 2016; 11(2):e0148304. PubMed ID: 26862894
[TBL] [Abstract][Full Text] [Related]
3. Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures.
Neumann PJ; Anderson JE; Panzer AD; Pope EF; D'Cruz BN; Kim DD; Cohen JT
Gates Open Res; 2018; 2():5. PubMed ID: 29431169
[No Abstract] [Full Text] [Related]
4. Measuring the Benefits of Healthcare: DALYs and QALYs - Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions.
Augustovski F; Colantonio LD; Galante J; Bardach A; Caporale JE; Zárate V; Chuang LH; Pichon-Riviere A; Kind P
Int J Health Policy Manag; 2018 Feb; 7(2):120-136. PubMed ID: 29524936
[TBL] [Abstract][Full Text] [Related]
5. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.
Niyibitegeka F; Thavorncharoensap M; Riewpaiboon A; Youngkong S
Appl Health Econ Health Policy; 2022 Sep; 20(5):707-716. PubMed ID: 35469393
[TBL] [Abstract][Full Text] [Related]
6. Global cost-effectiveness of cataract surgery.
Lansingh VC; Carter MJ; Martens M
Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
[TBL] [Abstract][Full Text] [Related]
7. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
Kim DD; Silver MC; Kunst N; Cohen JT; Ollendorf DA; Neumann PJ
Pharmacoeconomics; 2020 Oct; 38(10):1135-1145. PubMed ID: 32696192
[TBL] [Abstract][Full Text] [Related]
8. Use of Utility and Disability Weights in Economic Evaluation of Pediatric Vaccines.
Neppelenbroek NJM; de Wit GA; Dalziel K; Devlin N; Carvalho NI
Value Health; 2023 Jul; 26(7):1098-1106. PubMed ID: 36967026
[TBL] [Abstract][Full Text] [Related]
9. Patient Variability Seldom Assessed in Cost-effectiveness Studies.
Lavelle TA; Kent DM; Lundquist CM; Thorat T; Cohen JT; Wong JB; Olchanski N; Neumann PJ
Med Decis Making; 2018 May; 38(4):487-494. PubMed ID: 29351053
[TBL] [Abstract][Full Text] [Related]
10. When does quality-adjusting life-years matter in cost-effectiveness analysis?
Chapman RH; Berger M; Weinstein MC; Weeks JC; Goldie S; Neumann PJ
Health Econ; 2004 May; 13(5):429-36. PubMed ID: 15127423
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
[TBL] [Abstract][Full Text] [Related]
13. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
Ochalek J; Lomas J
Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
[TBL] [Abstract][Full Text] [Related]
14. Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs.
Mihalopoulos C; Magnus A; Lal A; Dell L; Forbes D; Phelps A
Aust N Z J Psychiatry; 2015 Apr; 49(4):360-76. PubMed ID: 25348698
[TBL] [Abstract][Full Text] [Related]
15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
16. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
17. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates.
Pandya A; Paulden M; Zhu J; Lavelle TA; Hammitt J
Med Decis Making; 2022 Oct; 42(7):885-892. PubMed ID: 35531945
[TBL] [Abstract][Full Text] [Related]
18. Taking stock of cost-effectiveness analysis of healthcare in China.
Butt T; Liu GG; Kim DD; Neumann PJ
BMJ Glob Health; 2019; 4(3):e001418. PubMed ID: 31179038
[TBL] [Abstract][Full Text] [Related]
19. Modeled cost-effectiveness of transforaminal lumbar interbody fusion compared with posterolateral fusion for spondylolisthesis using N(2)QOD data.
Carreon LY; Glassman SD; Ghogawala Z; Mummaneni PV; McGirt MJ; Asher AL
J Neurosurg Spine; 2016 Jun; 24(6):916-21. PubMed ID: 26895529
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive league table of cost-utility ratios: A systematic review of cost-effectiveness evidence for health policy decisions in India.
Shah K; Singh M; Kotwani P; Tyagi K; Pandya A; Saha S; Saxena D; Rajshekar K
Front Public Health; 2022; 10():831254. PubMed ID: 36311623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
